Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Evidence-based review of patient-reported outcomes with botulinum toxin type A. Clin Neuropharmacol 2004 Sep-Oct;27(5):234-44

Date

12/17/2004

Pubmed ID

15602105

DOI

10.1097/01.wnf.0000145508.84389.87

Scopus ID

2-s2.0-7444247368   28 Citations

Abstract

This review systematically examines the effects of botulinum toxin type A (BTX-A) on patient-reported outcomes across disorders using evidence-based criteria. The evidence provided by these studies ranged from randomized, controlled trials to case series. The effects of BTX-A on quality of life or global treatment outcomes were assessed in 48 studies across 16 different conditions. All but 7 of these reported benefits of BTX-A over baseline or the comparator condition (placebo or other treatment). The effects of BTX-A on impairment, activities, or participation were assessed in 46 studies across 17 different conditions. All but 4 reported benefits of BTX-A over baseline or the comparison group. The effects of BTX-A on satisfaction or preference were assessed in 14 studies across 11 different conditions, all of which reported high rates of satisfaction with BTX-A or preference over the comparator. These studies provide evidence that BTX-A exerts meaningful benefits on the quality of life of patients treated with this biologic agent.

Author List

Jankovic J, Esquenazi A, Fehlings D, Freitag F, Lang AM, Naumann M

Author

Frederick G. Freitag DO Professor in the Neurology department at Medical College of Wisconsin




MESH terms used to index this publication - Major topics in bold

Anti-Dyskinesia Agents
Botulinum Toxins, Type A
Evidence-Based Medicine
Humans
Movement Disorders
Patient Satisfaction
Quality of Life
Research Design
Treatment Outcome
jenkins-FCD Prod-409 d1e206b0be345926047b0d9c353c78a4cce4058b